The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Updates from the GEM-CLARIDEX study in myeloma
Noemí Puig, MD, PhD, of the University Hospital Salamanca, Salamanca, Spain, reports results from the GEM-CLARIDEX study (NCT02575144), evaluating lenalidomide and dexamethasone plus or minus clarithromycin in untreated, newly-diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
